Resch Hemma, Garhofer Gerhard
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Wien Med Wochenschr. 2006 Sep;156(17-18):501-7. doi: 10.1007/s10354-006-0335-0.
Glaucoma is defined as a progressive optic neuropathy involving characteristic structural changes in the optic nerve head and corresponding visual field defects. Elevated intraocular pressure (IOP) is a major risk and causative factor for glaucomatous optic neuropathy. Although mechanisms other than elevated IOP may contribute to the underlying pathophysiology of glaucoma, reducing IOP remains the primary goal of therapy. Recent clinical studies have shown that decreasing the IOP can delay, or in some cases prevent progression of this chronic ocular disease. Over the past decade, several new medical therapies have become available for the treatment of glaucoma. In this article a review of topical glaucoma therapy is presented.
青光眼被定义为一种进行性视神经病变，涉及视神经乳头的特征性结构变化及相应的视野缺损。眼压升高是青光眼性视神经病变的主要风险因素和致病因素。尽管眼压升高以外的机制可能导致青光眼的潜在病理生理过程，但降低眼压仍然是治疗的主要目标。最近的临床研究表明，降低眼压可以延缓，在某些情况下还可以预防这种慢性眼病的进展。在过去十年中，出现了几种用于治疗青光眼的新药物疗法。本文对局部青光眼治疗进行综述。
